Drotaverine

Summary

Drotaverine (CHEMBL551978) is a phase-3 clinical-stage small molecule (ATC A03AD02); indicated across 2 conditions including bile duct disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03AD02
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 397.5 Da · C24H31NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL551978
Name	Drotaverine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1712095
ATC	A03AD02
Molecular formula	C24H31NO4
Molecular weight	397.5
InChIKey	OMFNSKIUKYOYRG-MOSHPQCFSA-N

SMILES: CCOC1=C(C=C(C=C1)/C=C\2/C3=CC(=C(C=C3CCN2)OCC)OCC)OCC

IUPAC name: (1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-3,4-dihydro-2H-isoquinoline

Also known as: Drotaverin, Drotaverina, Drotaverine, Drotin, DROTAVERINE, drotaverine

Parent form; salt/anhydrous children: CHEMBL5483040

Patent coverage: 367 distinct patent families (1,459 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,451 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Prostaglandin G/H synthase 1, Sodium-dependent serotonin transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, 3’,5’-cyclic-AMP phosphodiesterase 4A, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4A	5.77	AC50	1685	nM	CHEMBL_ACT_25207150
KCNH2	5.54	AC50	2900	nM	CHEMBL_ACT_25117737
SLC6A4	5.52	AC50	2995	nM	CHEMBL_ACT_25151390
ADRA2A	5.23	AC50	5832	nM	CHEMBL_ACT_25156492
PTGS1	5.03	AC50	9332	nM	CHEMBL_ACT_25205287

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bile duct disorder	3	MONDO:0002887	MONDO:0002887

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00292747	PHASE4	TERMINATED	Drotaverine in Dysmenorrhoea Treatment
NCT01639027	PHASE2/PHASE3	COMPLETED	Drotaverine to Shorten the Length of Labor
NCT01236651	PHASE2	UNKNOWN	Meperidine Versus Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).